Novel bioresorbable stent coating for drug release in congenital heart disease applications

Amy C. Goodfriend, Tré R. Welch*, Greg Barker, Richard Ginther, Matthew S. Riegel, Surendranath Veeram Reddy, Jian Wang, Alan Nugent, Joseph Forbess

*Corresponding author for this work

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

A novel double opposed helical poly-l-lactic acid (PLLA) bioresorbable stent has been designed for use in pediatrics. The aim was to test the PLLA stent biocompatibility. The PLLA stent was immersed into whole pig's blood in a closed loop circuit then fibrin and platelet association was assessed via enzyme-linked immunosorbent assay. D-Dimer was valued at 0.2 ± 0.002 ng/mL and P-selectin 0.43 ± 00.01 ng/mL indicating limited association of fibrin and platelets on the stent. To improve biocompatibility by targeting inflammatory cells, dexamethasone was incorporated on PLLA fibers with two coating methods. Both coatings were poly(l-lactide-co-glycolide) acid (PLGA) but one was made porous with sucrose while the other remained nonporous. There was no change in mechanical properties of the fiber with either coating of PLGA polymer. The total amount of dexamethasone released was then determined for each coating. The cumulative drug release for the porous fiber was significantly higher (∼100%) over 8 weeks than the nonporous fiber (40%). Surface examination of the fiber with scanning electron microscopy showed more surface microfracturing in coatings that contain pores. The biocompatibility of this novel stent was demonstrated. Mechanical properties of the fiber were not altered by coating with PLGA polymer. Anti-inflammatory drug release was optimized using a porous PLGA polymer.

Original languageEnglish (US)
Pages (from-to)1761-1770
Number of pages10
JournalJournal of Biomedical Materials Research - Part A
Volume103
Issue number5
DOIs
StatePublished - May 1 2015

Fingerprint

Stents
Lactic acid
Coatings
Fibers
Lactic Acid
Biocompatibility
Pharmaceutical Preparations
Polymers
Acids
Platelets
Fibrin
Dexamethasone
Association reactions
Mechanical properties
Immunosorbents
Pediatrics
P-Selectin
Sugar (sucrose)
Dimers
Sucrose

Keywords

  • PLLA stent
  • bioresorbable polymer
  • dexamethasone
  • hemocompatability
  • pediatrics

ASJC Scopus subject areas

  • Ceramics and Composites
  • Biomaterials
  • Biomedical Engineering
  • Metals and Alloys

Cite this

Goodfriend, Amy C. ; Welch, Tré R. ; Barker, Greg ; Ginther, Richard ; Riegel, Matthew S. ; Reddy, Surendranath Veeram ; Wang, Jian ; Nugent, Alan ; Forbess, Joseph. / Novel bioresorbable stent coating for drug release in congenital heart disease applications. In: Journal of Biomedical Materials Research - Part A. 2015 ; Vol. 103, No. 5. pp. 1761-1770.
@article{8db69ba708e04b749455de1462528e9e,
title = "Novel bioresorbable stent coating for drug release in congenital heart disease applications",
abstract = "A novel double opposed helical poly-l-lactic acid (PLLA) bioresorbable stent has been designed for use in pediatrics. The aim was to test the PLLA stent biocompatibility. The PLLA stent was immersed into whole pig's blood in a closed loop circuit then fibrin and platelet association was assessed via enzyme-linked immunosorbent assay. D-Dimer was valued at 0.2 ± 0.002 ng/mL and P-selectin 0.43 ± 00.01 ng/mL indicating limited association of fibrin and platelets on the stent. To improve biocompatibility by targeting inflammatory cells, dexamethasone was incorporated on PLLA fibers with two coating methods. Both coatings were poly(l-lactide-co-glycolide) acid (PLGA) but one was made porous with sucrose while the other remained nonporous. There was no change in mechanical properties of the fiber with either coating of PLGA polymer. The total amount of dexamethasone released was then determined for each coating. The cumulative drug release for the porous fiber was significantly higher (∼100{\%}) over 8 weeks than the nonporous fiber (40{\%}). Surface examination of the fiber with scanning electron microscopy showed more surface microfracturing in coatings that contain pores. The biocompatibility of this novel stent was demonstrated. Mechanical properties of the fiber were not altered by coating with PLGA polymer. Anti-inflammatory drug release was optimized using a porous PLGA polymer.",
keywords = "PLLA stent, bioresorbable polymer, dexamethasone, hemocompatability, pediatrics",
author = "Goodfriend, {Amy C.} and Welch, {Tr{\'e} R.} and Greg Barker and Richard Ginther and Riegel, {Matthew S.} and Reddy, {Surendranath Veeram} and Jian Wang and Alan Nugent and Joseph Forbess",
year = "2015",
month = "5",
day = "1",
doi = "10.1002/jbm.a.35313",
language = "English (US)",
volume = "103",
pages = "1761--1770",
journal = "Journal of Biomedical Materials Research - Part A",
issn = "1549-3296",
publisher = "John Wiley and Sons Inc.",
number = "5",

}

Novel bioresorbable stent coating for drug release in congenital heart disease applications. / Goodfriend, Amy C.; Welch, Tré R.; Barker, Greg; Ginther, Richard; Riegel, Matthew S.; Reddy, Surendranath Veeram; Wang, Jian; Nugent, Alan; Forbess, Joseph.

In: Journal of Biomedical Materials Research - Part A, Vol. 103, No. 5, 01.05.2015, p. 1761-1770.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Novel bioresorbable stent coating for drug release in congenital heart disease applications

AU - Goodfriend, Amy C.

AU - Welch, Tré R.

AU - Barker, Greg

AU - Ginther, Richard

AU - Riegel, Matthew S.

AU - Reddy, Surendranath Veeram

AU - Wang, Jian

AU - Nugent, Alan

AU - Forbess, Joseph

PY - 2015/5/1

Y1 - 2015/5/1

N2 - A novel double opposed helical poly-l-lactic acid (PLLA) bioresorbable stent has been designed for use in pediatrics. The aim was to test the PLLA stent biocompatibility. The PLLA stent was immersed into whole pig's blood in a closed loop circuit then fibrin and platelet association was assessed via enzyme-linked immunosorbent assay. D-Dimer was valued at 0.2 ± 0.002 ng/mL and P-selectin 0.43 ± 00.01 ng/mL indicating limited association of fibrin and platelets on the stent. To improve biocompatibility by targeting inflammatory cells, dexamethasone was incorporated on PLLA fibers with two coating methods. Both coatings were poly(l-lactide-co-glycolide) acid (PLGA) but one was made porous with sucrose while the other remained nonporous. There was no change in mechanical properties of the fiber with either coating of PLGA polymer. The total amount of dexamethasone released was then determined for each coating. The cumulative drug release for the porous fiber was significantly higher (∼100%) over 8 weeks than the nonporous fiber (40%). Surface examination of the fiber with scanning electron microscopy showed more surface microfracturing in coatings that contain pores. The biocompatibility of this novel stent was demonstrated. Mechanical properties of the fiber were not altered by coating with PLGA polymer. Anti-inflammatory drug release was optimized using a porous PLGA polymer.

AB - A novel double opposed helical poly-l-lactic acid (PLLA) bioresorbable stent has been designed for use in pediatrics. The aim was to test the PLLA stent biocompatibility. The PLLA stent was immersed into whole pig's blood in a closed loop circuit then fibrin and platelet association was assessed via enzyme-linked immunosorbent assay. D-Dimer was valued at 0.2 ± 0.002 ng/mL and P-selectin 0.43 ± 00.01 ng/mL indicating limited association of fibrin and platelets on the stent. To improve biocompatibility by targeting inflammatory cells, dexamethasone was incorporated on PLLA fibers with two coating methods. Both coatings were poly(l-lactide-co-glycolide) acid (PLGA) but one was made porous with sucrose while the other remained nonporous. There was no change in mechanical properties of the fiber with either coating of PLGA polymer. The total amount of dexamethasone released was then determined for each coating. The cumulative drug release for the porous fiber was significantly higher (∼100%) over 8 weeks than the nonporous fiber (40%). Surface examination of the fiber with scanning electron microscopy showed more surface microfracturing in coatings that contain pores. The biocompatibility of this novel stent was demonstrated. Mechanical properties of the fiber were not altered by coating with PLGA polymer. Anti-inflammatory drug release was optimized using a porous PLGA polymer.

KW - PLLA stent

KW - bioresorbable polymer

KW - dexamethasone

KW - hemocompatability

KW - pediatrics

UR - http://www.scopus.com/inward/record.url?scp=84925794859&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925794859&partnerID=8YFLogxK

U2 - 10.1002/jbm.a.35313

DO - 10.1002/jbm.a.35313

M3 - Article

C2 - 25196819

AN - SCOPUS:84925794859

VL - 103

SP - 1761

EP - 1770

JO - Journal of Biomedical Materials Research - Part A

JF - Journal of Biomedical Materials Research - Part A

SN - 1549-3296

IS - 5

ER -